Insulin Reduction

The unique insulin delivery of V-Go lowered basal-bolus requirements and A1c significantly more than multiple daily injections (MDI).₁

In patients who switched to V-Go from MDI, basal and bolus insulin requirements were reduced by 40% and 48%, respectively.₁

_{Study Design: Based on a real-world, retrospective analysis of an electronic medical records database. Patients were adults diagnosed with diabetes mellitus, A1c >7.0%, and previously prescribed basal-bolus insulin therapy.}

_{Individual results may vary.}

MDI=multiple daily injections.
TDD=Total Daily Dose
*P<0.0001 compared with baseline.

Proven Effective Regardless of Patient’s Baseline Insulin Dose

Patients prescribed V-Go saw significant A1C and insulin reductions vs those on MDI.₂

MDI=multiple daily injections.
*P<0.0001 compared with baseline.

View Baseline Characteristics

V-Go optimizes basal insulin delivery and supports adherence to mealtime insulin.

Study Design: Electronic medical records were queried to identify patients switched from previous insulin therapy to insulin delivery with V-Go. In all, 104 patients were stratified by moderate baseline insulin doses (<100 U/day) or high baseline insulin doses (≥100 U/day; n=38) and compared using total daily dose U/day and U/kg. A1c and average prescribed insulin dosing were collected at baseline and for 2 follow-up A1c results on V-Go (the VALIDATE study).

SCHEDULE A LIVE VIDEO CHAT REQUEST A NEW PATIENT STARTER KIT

References: Reference: 1. Lajara R, Nikkel C. Evaluating the effect of V-Go therapy in sub-optimally controlled patients with diabetes: a retrospective cohort analysis in a large specialized diabetes system. Presented at: ISPOR. May 2017. 2. Lajara R, Nikkel C. Using V-Go wearable insulin delivery device in patients prescribed high insulin doses: a comparison of clinical results between high and moderate insulin dose groups. Poster presented at: Diabetes Technology Meeting; October 2015; Bethesda, MD.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

V-Go® Resulted in Lower Insulin Requirements

Proven Effective Regardless of Patient’s Baseline Insulin Dose

V-Go optimizes basal insulin delivery and supports adherence to mealtime insulin.

Important Risk Information